Company Announcements

Illumina announced in January that its 2013 organic investments will include the addition of 50 sales representatives for improved geographic reach, incremental R&D investments and infrastructure enhancements.

Becton, Dickinson and Company appointed Catherine M. Burzik to its Board in January. Most recently, she was CEO of Kinetic Concepts.

QIAGEN currency-neutral fourth-quarter 2012 revenues grew 4.0%, including 2% growth from the AmniSure acquisition (see IBO 6/15/12), to $346.5 million (see IBO 1/31/13). Molecular Diagnostics and Life Sciences sales grew 6% and 2% excluding currency to make up 52% and 48% of sales, respectively. Adjusted operating profit rose 10.9% to $106.0 million. In 2012, revenues grew 7.3%, 4% organically, to $1,254.5 million. Acquisitions contributed 6% to revenue growth, and currency lowered sales growth by 3%. Instruments, and consumables and related revenues grew 11% and 10% excluding currency to make up 14% and 86% of sales, respectively. Excluding currency, Molecular Diagnostics, Applied Testing, Pharma and Academia sales grew 15%, 22%, 5% and 1% to make up 49%, 8%, 19% and 24% of revenues, respectively. Currency-neutral sales to the Americas, Europe/Middle East/Africa and Asia-Pacific/Japan grew 8%, 9% and 15% to represent 46%, 34% and 19% of total sales, respectively. Adjusted operating profit expanded 11.6% to $356.4 million. In 2013, currency-neutral sales are expected to grow 5%–6%.

QIAGEN named Dr. Tadd S. Lazarus chief medical officer. He was formerly chief medical officer and vice president of Clinical Affairs at Gen-Probe.

Roche Applied Science 2012 sales were flat, but declined 3% excluding currency to CHF 737 million ($784 million) to make up 7% of Diagnostics sales. At constant exchange rates, Custom Biotech sales rose 8%, qPCR & Nucleic Acid Purification sales rose 5% and Genomic Analysis sales fell 19%. Excluding currency, Rest of World sales rose 3%, but sales in Europe, Middle East and Africa (EMEA), and North America declined 5% each to make up 25%, 38% and 37% of revenue, respectively.

Fourth-quarter 2012 sales for the Test unit of Xylem’s Water Infrastructure segment grew 1%. Test 2012 revenue was $298 million, with the acquisitions of YSI (see IBO 7/15/11) and MJK Automation (see IBO 7/15/12) adding $90 million in sales. Europe, the US, Asia Pacific and Other made up 41%, 28%, 21% and 10% of Test revenue, respectively, while lab, field monitoring, field sampling and online products accounted for 33%, 32%, 25% and 10%, respectively.

Corning Life Sciences 2012 revenue rose 10% to $657 million, including $236 million in sales for Discovery Labware. Sales in 2013 are forecast to grow around 15%.

Danaher announced in February that Mortimer M. Caplin will resign from its Board in May.

In February, Bruker named Dr. Marc Kastner, Donner Professor of Physics and dean of the School of Science at MIT, to its Board, replacing CFO Charles F. Wagner, Jr.